c-Jun N-Terminal Kinase Inhibitors as Potential Leads for New Therapeutics for Alzheimer's Diseases.
c-Jun N-Terminal Kinase Inhibitors as Potential Leads for New Therapeutics for Alzheimer's Diseases.
复制标题
DOI:
10.3390/ijms21249677
复制
发表时间:
2020-12-18
影响因子:
5.6
通讯作者:
Laufer S
中科院分区:
文献类型:
--
作者:
Hepp Rehfeldt SC;Majolo F;Goettert MI;Laufer S
Alzheimer’s Disease (AD) is becoming more prevalent as the population lives longer. For individuals over 60 years of age, the prevalence of AD is estimated at 40.19% across the world. Regarding the cognitive decline caused by the disease, mitogen-activated protein kinases (MAPK) pathways such as the c-Jun N-terminal kinase (JNK) pathway are involved in the progressive loss of neurons and synapses, brain atrophy, and augmentation of the brain ventricles, being activated by synaptic dysfunction, oxidative stress, and excitotoxicity. Nowadays, AD symptoms are manageable, but the disease itself remains incurable, thus the inhibition of JNK3 has been explored as a possible therapeutic target, considering that JNK is best known for its involvement in propagating pro-apoptotic signals. This review aims to present biological aspects of JNK, focusing on JNK3 and how it relates to AD. It was also explored the recent development of inhibitors that could be used in AD treatment since several drugs/compounds in phase III clinical trials failed. General aspects of the MAPK family, therapeutic targets, and experimental treatment in models are described and discussed throughout this review.
登录
查看更多内容
影响因子:
3.6
作者:
Ahmadi, Shamseddin;Khaledi, Shiler
通讯作者:
Khaledi, Shiler
DOI:
10.1016/j.bbapap.2009.11.002
发表时间:
2010-03-01
影响因子:
3.2
作者:
Bogoyevitch, Marie A.;Ngoei, Kevin R. W.;Ng, Dominic C. H.
通讯作者:
Ng, Dominic C. H.
影响因子:
3.7
作者:
Arnold, Steven E.;Hyman, Bradley T.;Van Hoesen, Gary W.
通讯作者:
Van Hoesen, Gary W.
影响因子:
3.4
作者:
Blease, Kate;Lewis, Alan;Raymon, Heather K
通讯作者:
Raymon, Heather K
影响因子:
64.8
作者:
Chang, LF;Karin, M
通讯作者:
Karin, M